Group 1 - The core viewpoint of the article is that Saintong Special Medical (Qingdao) Nutrition Health Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - Saintong Special Medical is recognized as one of China's leading providers of special medical foods, focusing on the development, production, and sales of these products [1] - The company ranks first among domestic special medical food brands in China, holding a market share of 6.3% in the overall special medical food market and 9.5% in the infant special medical food market, where it also ranks first among domestic brands [1] Group 2 - The special medical food market in China is highly concentrated, with the top five players accounting for 78.0% of the market share, while the infant special medical food market has an even higher concentration, with the top five brands holding 92.9% of the market share [1]

Core Viewpoint - 圣桐特医 is applying for a listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, highlighting its growth and leadership in the specialized medical food market in China [1][4]. Company Overview - 圣桐特医 is recognized as one of China's leading providers of specialized medical foods, focusing on the development, production, and sales of these products [4]. - The company holds the top position among domestic specialized medical food brands in China, with a market share of 6.3% in the overall specialized medical food market and 9.5% in the infant specialized medical food segment [4]. Product Development - Since its establishment in 2005, 圣桐特医 has pioneered the specialized medical food sector in China, launching the first commercialized specialized medical food product in 2007 [4]. - The company has introduced 14 major specialized medical food products as of May 20, 2025, with 16 additional products currently in development [5]. Financial Performance - The revenue for 圣桐特医 has shown significant growth, with figures of approximately 491.2 million RMB in 2022, 654.2 million RMB in 2023, and projected 834.1 million RMB in 2024 [5][7]. - The adjusted net profit (non-IFRS) for the same periods was approximately 121 million RMB, 175 million RMB, and 199 million RMB, respectively [5][7].